Skip to main content

MK7902-007 A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score

NCT03829332

A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Merck Sharp & Dohme

The purpose of this study is to: Test the safety of the study drugs, lenvatinib and pembolizumab, when given together. See how well they work compared to pembrolizumab plus placebo (a lenvatinib look-alike with no active ingredients). See how your body handles the study drugs. See if the study drugs help patients live longer Pembrolizumab (MK-3475), also known as KEYTRUDA, and lenvatinib (E7080), also known as Lenvima, have been approved by certain health authorities for the treatment of various cancers. However, they may not be approved for your exact type of cancer in your country. Getting lenvatinib and pembrolizumab together is considered experimental.